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Abstract The low density lipoprotein receptor-related protein
(LRP) is a multifunctional cell surface receptor highly ex-
pressed in human aortic smooth muscle cells. In the present
study, we used the short interfering RNA (siRNA) technique
to explore the role of LRP in smooth muscle cell migration.
We identi¢ed an LRP-speci¢c siRNA that selective silences
LRP expression in human aortic smooth muscle cells. As a
consequence, LRP-mediated ligand degradation was signi¢-
cantly reduced. More important, we found that platelet-derived
growth factor-dependent cell migration was inhibited in cells
transfected with LRP siRNA. These results demonstrate an
important role of LRP in smooth muscle cell migration.
' 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The low density lipoprotein receptor (LDLR)-related pro-
tein (LRP) is a large endocytic receptor that belongs to the
emerging LDLR family. LRP binds and endocytoses over 30
structurally and functionally distinct ligands including apoli-
poprotein E/lipoproteins, proteinases, proteinase^inhibitor
complexes, and extracellular matrix proteins [1,2]. Ligand in-
teraction with LRP can be antagonized by a 39-kDa receptor-
associated protein (RAP), a molecular chaperone that assists
the folding and tra⁄cking of LRP [3]. Increasing evidence has
shown that LRP plays important roles in lipoprotein remnant
catabolism, protease regulation, cell migration, neurotrans-
mission, and signal transduction [1].
Smooth muscle cell proliferation and migration are essential
features of vasculogenesis and blood vessel maturation and
clearly play roles in the pathophysiology of several prominent
cardiovascular disease states, such as atherosclerosis and
restenosis [4,5]. LRP is present in macrophages and vascular
smooth muscle cells from atherosclerotic lesions and from
normal vessels [6^10]. Cellular uptake of aggregated low den-
sity lipoprotein by LRP may promote foam cell formation
[11]. Internalization of apolipoprotein E, proteinase^inhibitor
complexes, and K-defensin by LRP may alter vascular smooth
muscle cell migration and contraction [12^15]. Furthermore, a
compelling recent study has shown that inactivation of LRP
in vascular smooth muscle cells in mice results in marked
susceptibility to cholesterol-induced atherosclerosis [16].
Recent studies have revealed that RNA interference, a pro-
cess of homology-dependent degradation of cognate mRNA
by double-stranded RNA, is a powerful tool to inhibit gene
expression [17]. This phenomenon is commonly present in
fungi, plants, and nematodes. In mammalian cells, selective
degradation of target mRNAs is achieved by transfection
with short interfering (21 bp) duplex RNAs (siRNAs), leading
to rapid and e⁄cient degradation of the target [18,19]. E¡ec-
tive siRNA for members of the LDLR family, LRP in partic-
ular, has not been reported to date. To directly address the
importance of LRP in smooth muscle cell migration, we de-
signed several siRNAs against LRP and tested their e¡ective-
ness in suppressing LRP expression. We show that siRNA-
mediated suppression of LRP expression results in a signi¢-
cant inhibition of LRP-mediated ligand degradation and
smooth muscle cell migration.
2. Materials and methods
2.1. Reagents
Human K2-macroglobulin (K2M) was puri¢ed from human plasma
and activated with methylamine (K2M*) as described [20]. Human
recombinant RAP was expressed as a glutathione S-transferase fusion
protein and was isolated as described previously [21]. Human two-
chain urokinase plasminogen activator (uPA) was obtained by limited
plasmin digestion of recombinant human single-chain uPA [22]. Plate-
let-derived growth factor-BB (PDGF-BB) was from Invitrogen. Re-
combinant human plasminogen activator inhibitor type 1 (PAI-1) was
from American Diagnostica. Monoclonal antibody 8G1 against hu-
man LRP was from Research Diagnostics. Polyclonal anti-RAP anti-
body has been described before [23]. Monoclonal anti-actin antibody
was from Sigma. Transwell cell culture chambers were from Costar.
Carrier-free Na125I was purchased from Perkin-Elmer Life Sciences.
Proteins were iodinated using the IODO-GEN method as described
previously for RAP [24]. [125I]uPA^PAI-1 complexes were prepared by
the method described [25].
2.2. Cell culture and transfection
Human glioblastoma U87 cells were cultured in Dulbecco’s mini-
mum essential medium supplemented with 10% fetal bovine serum,
2 mM L-glutamine, 100 U/ml penicillin, 100 Wg/ml streptomycin, 1 mM
sodium pyruvate, and maintained at 37‡C in humidi¢ed air containing
5% CO2. Human breast cancer MCF-7 cells were cultured in the same
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conditions as for U87 cells, except that its medium contains no so-
dium pyruvate. Human aortic smooth muscle cells were purchased
from Clonetics (San Diego, CA, USA) and were cultured under stan-
dard culture conditions according to the manufacturer’s protocol.
Single-stranded, LRP-speci¢c sense and antisense RNA oligonu-
cleotides were synthesized by Ambion (Austin, TX, USA). Double-
stranded RNA molecules were generated according to the manufac-
turer’s instructions. For transfection, cells were trypsinized and seeded
into six-well plates (2.0U105 cells/well) without antibiotics. After 24 h,
cells were transfected with siRNA using Lipofectamine2000 (Invitro-
gen) according to the manufacturer’s speci¢cations. siRNAs were used
at a concentration of 120 nM in transfections. The ¢nal volume of
culture medium was 2.0 ml/well. Cells were harvested for analysis 48 h
after transfection.
2.3. Western blotting
U87, MCF-7, and human aortic smooth muscle cells were lysed
with 0.5 ml of lysis bu¡er (phosphate-bu¡ered saline containing 1%
Triton X-100 and 1 mM phenylmethylsulfonyl £uoride) at 4‡C for 30
min. Equal quantities of protein were subjected to sodium dodecyl
sulfate^polyacrylamide gel electrophoresis (SDS^PAGE) under non-
reducing conditions. Following transfer to Immobilon-P transfer
membrane, successive incubations with anti-LRP antibody 8G1,
anti-RAP antibody, or anti-actin antibody and horseradish peroxi-
dase-conjugated secondary antibody were carried out for 60 min at
room temperature. The immunoreactive proteins were then detected
using the ECL system. Films showing immunoreactive bands were
scanned by Kodak Digital Science DC120 zoom digital camera and
analyzed with Kodak Digital Science1D image analysis software.
2.4. Ligand degradation
Ligand degradation was performed using the methods as described
[24]. Brie£y, 2U105 cells were seeded into 12-well dishes 1 day prior to
assays. Pre-warmed assay bu¡er (minimal Eagle’s medium containing
0.6% bovine serum albumin (BSA) with radioligand, 0.6 ml/well) was
added to cell monolayers in the absence or presence of unlabeled 500
nM RAP, followed by incubation for 4 h at 37‡C. Thereafter, the
medium overlying the cell monolayers was removed and proteins
were precipitated by addition of BSA to 10 mg/ml and trichloroacetic
acid to 20%. Degradation of radioligand was de¢ned as the appear-
ance of radioactive fragments in the overlying medium that were
soluble in 20% trichloroacetic acid. The protein concentration of
each cell lysate was measured in parallel dishes that did not contain
LRP ligands.
2.5. Cell migration assay
Cell migration assays were carried out in 6.5-mm Transwell cham-
bers as described [12], with minor modi¢cations. Twenty-four hours
after siRNA transfection, human aortic smooth muscle cells were
made quiescent for 24 h with SmGM-2 medium (Clonetics) and
0.4% fetal bovine serum. Cells were harvested, washed, and resus-
pended in the same medium, and placed in the upper compartment
of the Transwell chambers (5U104 cells in 100 Wl). The lower com-
partment was ¢lled with 600 Wl SmGM-2, 0.4% fetal bovine serum,
and 0.1% BSA, with or without 30 ng/ml PDGF-BB. After incubation
for 4 h at 37‡C, cells on the lower surface of the ¢lter were ¢xed and
stained, and eight random ¢elds/¢lter were counted at U200 magni-
¢cation.
3. Results
3.1. LRP is highly expressed in human aortic smooth muscle
cells
LRP is highly expressed in vascular smooth muscle cells.
The presence of LRP in human aortic smooth muscle cells
was veri¢ed by Western blotting using LRP-speci¢c antibody.
In previous studies, we found that human breast cancer MCF-
7 cells express only trace amounts of LRP [26], while human
glioblastoma U87 cells express large amounts of LRP [27]. To
assess the relative expression of LRP in human aortic smooth
muscle cells, we used these two cell lines as controls. Fig. 1A
shows a Western blotting analysis comparing the LRP expres-
sion in human aortic smooth muscle cells with MCF-7 cells
Fig. 1. LRP expression in human aortic smooth muscle cells. A:
Western blotting analysis of LRP expression. Cell extracts from
MCF-7 cells, U87 cells, and human aortic smooth muscle cells were
separated via SDS^PAGE and analyzed by Western blotting with
anti-LRP antibody 8G1. B: K2M* degradation in human aortic
smooth muscle cells. MCF cells, U87 cells, and human aortic
smooth muscle cells were incubated with [125I]K2M* (1.25 nM) at
37‡C for 4 h in the absence or presence of 500 nM RAP. The deg-
radation of [125I]K2M* was analyzed as described in Section 2. Val-
ues are the average speci¢c degradation of triple determinations
with the S.D. indicated by error bars. This experiment is representa-
tive of two such experiments performed with similar data.
Table 1
LRP siRNA sequences
LRP siRNA#1 Targeted region (cDNA) 73AAGACTTGCAGCCCCAAGCAG93
Sense siRNA GACUUGCAGCCCCAAGCAGtt
Antisense siRNA CUGCUUGGGGCUGCAAGUCtt
LRP siRNA#2 Targeted region (cDNA) 88AAGCAGTTTGCCTGCAGAGAT108
Sense siRNA GCAGUUUGCCUGCAGAGAUtt
Antisense siRNA AUCUCUGCAGGCAAACUGCtt
LRP siRNA#3 Targeted region (cDNA) 114AACCTGTATCTCAAAGGGCTG134
Sense siRNA CCUGUAUCUCAAAGGGCUGtt
Antisense siRNA CAGCCCUUUGAGAUACAGGtt
LRP siRNA#4 Targeted region (cDNA) 222AAACGAGCATAACTGCCTGGG242
Sense siRNA ACGAGCAUAACUGCCUGGGtt
Antisense siRNA CCCAGGCAGUUAUGCUCGUtt
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and U87 cells. As seen in the ¢gure, human aortic smooth
muscle cells express abundant LRP. The LRP band intensity
from human aortic smooth muscle cells was about two times
greater than that from U87 cells. To characterize the function
of LRP in human aortic smooth muscle cells, we examined
ligand degradation mediated by LRP using a LRP-speci¢c
ligand, K2M* (Fig. 1B). As expected, human aortic smooth
muscle cells displayed a high degree of K2M* degradation.
The level of LRP-mediated K2M* degradation by human
aortic smooth muscle cells was about 2.0 times greater than
that by U87 cells.
3.2. Speci¢c inhibition of LRP expression by LRP siRNA
We next examined the e¡ects of LRP siRNA on LRP ex-
pression in human aortic smooth muscle cells. We designed
four double-stranded, 21-nucleotide-long siRNAs with TT di-
nucleotide 3P overhangs against the coding sequence of human
LRP (GI 4758685) (Table 1). None of the siRNAs shares
homology with exons of other known human genes. Human
aortic smooth muscle cells were transfected with these four
di¡erent LRP siRNAs, and LRP expression was assessed by
Western blotting. As seen in Fig. 2, LRP siRNA#4 had no
e¡ect on LRP expression, and LRP siRNA#1 and #3 sup-
pressed LRP expression to a moderate degree. Signi¢cantly,
LRP siRNA#2 silenced LRP expression by more than 90%,
suggesting that LRP siRNA#2 is a powerful tool for modu-
lating LRP expression. The di¡erences in e¡ectiveness of dif-
ferent LRP siRNAs were not due to the transfection e⁄-
ciency. We found a similar LRP reduction pattern in LRP
siRNA-treated human lung cancer cell lines (data not shown).
The reduction of LRP expression was maintained for as long
as 72 h after transfection with LRP siRNA (data not shown).
3.3. LRP ligand degradation is inhibited in smooth muscle cells
transfected with LRP siRNA
We then examined whether the siRNA-mediated suppres-
sion of LRP expression results in reduced ligand degradation.
We used LRP siRNA#4 as the negative control, as the e¡ect
of this siRNA duplex on LRP expression is negligible. We
chose two well-characterized LRP ligands, K2M* and uPA^
PAI-1 complex, as test ligands. As seen in Fig. 3, when LRP
siRNA#2 was applied in human aortic smooth muscle cells,
inhibition of K2M* degradation and uPA^PAI-1 degradation
was 63% and 72%, respectively. These results demonstrate
that LRP siRNA#2 inhibits LRP-mediated ligand degrada-
tion.
Fig. 2. Speci¢c inhibition of LRP expression by siRNA. A: E¡ect
of siRNAs, targeted toward four di¡erent sites (1^4) in the LRP
coding region, on LRP expression. Human aortic smooth muscle
cells were transfected with four di¡erent LRP siRNAs or treated
with Lipofectamine2000 only (LP2000). LRP expression was mea-
sured by SDS^PAGE and Western blotting 48 h after transfection.
The same amounts of lysates were analyzed by Western blotting
with either anti-RAP antibody or anti-actin antibody, indicating
that the same amounts of protein were loaded under each condition.
B: Densitometric analysis of LRP expression presented in A. This
experiment is representative of three such experiments performed
with similar data.
Fig. 3. LRP-mediated ligand degradation is inhibited in smooth
muscle cells transfected with the LRP siRNA. Human aortic smooth
muscle cells were transfected with LRP siRNA#2, siRNA#4, or
treated with Lipofectamine2000 only (LP2000). Forty-eight hours
after transfection, cells were incubated with [125I]K2M* (1.25 nM) or
[125I]uPA^PAI-1 (5 nM) at 37‡C for 4 h in the absence or presence
of 500 nM RAP. The degradation of [125I]K2M* and [125I]uPA^
PAI-1 complex was analyzed as described in Section 2. Values are
the average speci¢c degradation of triple determinations with the
S.D. indicated by error bars. This experiment is representative of
two such experiments performed with similar data.
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3.4. Cell migration is inhibited in LRP siRNA-transfected
smooth muscle cells
Several members of the LDLR family are involved in vas-
cular smooth muscle cell migration. Incubation of human
aortic smooth muscle cells with 500 nM RAP resulted in
approximately 90% inhibition of PDGF-directed cell migra-
tion (Fig. 4A). To investigate the role of LRP in human aortic
smooth muscle cell migration, we employed LRP siRNA. As
seen in Fig. 4B, treatment of human aortic smooth muscle
cells with LRP siRNA#2 resulted in about 50% inhibition
of PDGF-directed cell migration. The 24 h quiescence with
SmGM-2 medium and 0.4% fetal bovine serum had no e¡ect
on LRP reduction upon siRNA treatment (data not shown).
Cell migration in the absence of PDGF was minimal and was
not signi¢cantly a¡ected by LRP inhibition (Fig. 4B).
4. Discussion
The very large size of LRP (V600 kDa) limits molecular
manipulations at the cDNA level and the expression of this
protein via transfection. In addition, LRP knockout in mice
results in early embryonic lethality [28]. The recent develop-
ment of the siRNA technique in mammalian cells has
prompted us to explore the use of siRNA to moderate LRP
expression. In the present study, we identi¢ed that, of the four
LRP siRNAs tested, LRP siRNA#2 is the most e¡ective in
inhibiting LRP expression.
Human aortic smooth muscle cells express high level of
LRP, which endocytoses and degrades over 30 di¡erent li-
gands [1]. In the present study, we chose K2M* and uPA^
PAI-1 to study ligand degradation. LRP siRNA#2 suppressed
more than 90% of LRP expression in human aortic smooth
muscle cells, and resulted in 60^70% inhibition of ligand deg-
radation. Smooth muscle cells express several members of the
LDLR family including LRP1B (our unpublished data) and
the very low density lipoprotein receptor [8,9,29]. When LRP
expression is suppressed, human aortic smooth muscle cells
could still maintain some levels of uPA^PAI-1 complex deg-
radation via the very low density lipoprotein receptor and
LRP1B, and of K2M* degradation possibly via LRP1B.
In the present study, we found that treatment with LRP
siRNA or RAP inhibits human aortic smooth muscle cell
migration in response to PDGF. This is consistent with results
reported previously by other studies [12^14]. It has been dem-
onstrated that inhibition of LRP function by either anti-LRP
antibody or RAP reduces smooth muscle cell migration in
response to uPA [13,14]. Despite these mounting studies, the
mechanism underlying LRP modulating of smooth muscle cell
migration is still not clear. LRP may promote uPA-induced
smooth muscle cell migration by enhancing regeneration of
unoccupied uPA receptor at the cell surface [13,30,31]. Alter-
natively, LRP may modulate the functional level of the PDGF
receptor, thereby regulating the signal transduction pathways
downstream of the PDGF receptor that participate in smooth
muscle cell migration [16,32,33]. Both apolipoprotein E and
RAP could interference with the binding of other ligand(s)
(e.g. uPA^PAI-1 complexes) to LRP, and subsequently inhibit
LRP function and smooth muscle cell migration.
The roles of LRP in regulation of cellular migration are not
limited to smooth muscle cells. LRP antisense RNA-trans-
fected HT1080 ¢brosarcoma cells and LRP-de¢cient ¢bro-
blasts demonstrate increased cell migration [34,35]. However,
RAP-treated breast cancer cells and myogenic cells display
decreased cell migration [26,36,37]. Furthermore, LRP-null
¢broblasts and RAP-treated endothelial cells do not migrate
in response to thrombospondin stimulation [38]. The disparity
of LRP function from these studies may re£ect diverse char-
acteristics of the experimental systems, including cell types,
LRP expression levels, expression levels of other members of
the LDLR family, and signaling pathways that participate in
cellular migration. Nevertheless, all these studies point out an
important role of LRP in cellular migration.
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